新型细冷冻探针经支气管冷冻消融周围肺实质的首次临床验证
研究先用18头猪验证8mm长、1.9mm宽冷冻探针经支气管冷冻消融的安全性与有效性,再对9例IA期周围型肺癌或转移瘤患者实施导航支气管镜联合锥形束CT引导下的冷冻消融。动物实验显示消融范围随冷冻时间和冻融循环次数增加,临床技术成功率100%,7/9肿瘤完全消融。
要点
- 新型细冷冻探针经支气管冷冻消融在猪模型中安全可行,无重大并发症。
- 临床9例患者10次消融技术成功率100%,仅1例轻度治疗相关并发症。
- 9个肿瘤中7个完全消融,2个不完全消融并在6个月时局部进展。
核心结论
- 经支气管冷冻消融对不可手术的周围型IA期肺癌或肺转移瘤是安全可行的。
研究设计与样本
- 动物实验:18头猪在CT监测下接受经支气管冷冻消融,使用8mm长、1.9mm宽冷冻探针,采用2或3个冻融循环,每次冷冻10或15分钟。
- 临床研究:9例IA期周围型肺癌或转移瘤患者,在导航支气管镜和锥形束CT引导下接受经支气管冷冻消融,评估技术成功、安全性和结局。
- 试验注册号:ChiCTR2200061544。
主要发现
- 猪模型共完成36次冷冻消融,无重大并发症。
- 消融范围随冷冻时间和冻融循环次数增加,在24小时达峰值后逐渐减小。
- 病理显示24小时为大片出血,4周后转为纤维增生伴慢性炎症。
- 临床对9个肿瘤完成10次冷冻消融,技术成功率100%,发生1例轻度治疗相关并发症。
- 9个肿瘤中7个完全消融,2个不完全消融并在6个月时局部进展。
临床怎么用
- 对不可手术的周围型IA期肺癌或肺转移瘤,可考虑经支气管冷冻消融作为局部治疗选择。
- 操作需在导航支气管镜和锥形束CT引导下进行,使用8mm长、1.9mm宽冷冻探针。
- 消融范围与冷冻时间和冻融循环次数相关,需根据病灶情况选择2或3个循环、每次10或15分钟。
局限性
- 临床样本量小(9例患者、9个肿瘤),仅为初步经验。
- 2个肿瘤不完全消融并出现局部进展,提示需关注消融完全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Transbronchial cryoablation shows potential as a local therapy for inoperable peripheral lung cancer. However, its clinical application for peripheral pulmonary lesions has not been reported yet. METHODS: An improved cryoprobe with an 8-mm-long, 1.9-mm-wide cryotip was used. Initially, the safety and effectiveness of this cryoprobe were assessed in an in vivo porcine model. Transbronchial cryoablation with 2 or 3 freeze-thaw cycles (10 min or 15 min in each freezing time) was performed in 18 pigs under CT monitoring. Radiological and pathological examinations were performed to evaluate the extent of cryoablation. Subsequently, nine patients with stage IA peripheral lung cancer or metastases underwent transbronchial cryoablation with this cryoprobe under the guidance of navigation bronchoscopy and cone-beam CT. Technical success, safety and outcomes were assessed. RESULTS: 36 cryoablation procedures were performed successfully without any major complications in the porcine model. The extent of cryoablation increased with freezing time and the number of freeze-thaw cycles, which peaked at 24 hours and then gradually decreased. Pathological results showed a change from massive haemorrhage at 24 hours to fibrous hyperplasia with chronic inflammation after 4 weeks. In the clinical trial, 10 cryoablations were performed on 9 tumours with a technical success rate of 100%. One mild treatment-related complication occurred. Of the nine tumours, seven achieved complete ablation, while two exhibited incomplete ablation and subsequent local progression at 6 months. CONCLUSION: Our initial experience indicated that transbronchial cryoablation was a safe and feasible procedure for non-surgical peripheral stage IA lung cancer or pulmonary metastases. TRIAL REGISTRATION NUMBER: ChiCTR2200061544.
引用
- Gu C, Yuan H, Yang C, et al. Transbronchial cryoablation in peripheral lung parenchyma with a novel thin cryoprobe and initial clinical testing. Thorax. 2024. PMID: 38242710. doi:10.1136/thorax-2023-220227
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。